ArticleKidney medicine2026
Growth Failure Associated With Parathyroid Hormone Levels in Pediatric Dialysis Patients: A Nationwide Cohort Study.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Growth failure is prevalent in pediatric dialysis patients. Physical growth is limited to a specific period, and missed interventions may cause lifelong growth retardation. We aimed to investigate the association of secondary hyperparathyroidism with short stature and height growth failure. Study Design: Cohort study. Setting & Participants: Patients aged 1-20 years who initiated dialysis and were registered in the nationwide dialysis registry of Japan between 2009 and 2020. Exposure: Intact parathyroid hormone (PTH) levels. Outcomes: Height standard deviation score (SDS), short stature (less than or equal to -2.0 SDS of height), height velocity SDS, and height growth failure (less than or equal to -1.5 SDS of height velocity). Analytical Approach: We examined the association between intact PTH levels and the outcomes in both cross-sectional and longitudinal analyses. Results: Intact PTH, height, and weight were measured in 622 patients. The median dialysis vintage was 10 months, the mean age was 13 years, 59% were boys, 50% were receiving peritoneal dialysis, and the median value of intact PTH was 183 pg/mL. At enrollment, the median height SDS was -1.9 (IQR, -3.3 to -0.6), and 302 patients (49%) had a short stature. The median SDS of height velocity during the first year was -2.4 (IQR, -5.6 to -1.5), and 205 patients (75%) had height growth failure (a decrease in height velocity). Elevated intact PTH levels per doubling were associated with a significant decrease in height velocity (β = -0.26; 95% CI, -0.49 to -0.02) and height growth failure (OR, 1.16; 95% CI, 1.00-1.34). Restricted cubic spline analysis showed a decrease in height velocity with increasing intact PTH levels. Limitations: Lacked data on recombinant human growth hormone use and limited follow-up periods to evaluate the impact of PTH on long-term growth. Conclusions: Our findings suggest the involvement of secondary hyperparathyroidism in height growth failure in pediatric dialysis patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.